A National Institutes of Health-supported nationwide clinical trial will test a novel approach to combat hearing loss in children infected by a relatively unknown virus, cytomegalovirus (CMV). CMV is ...
Please provide your email address to receive an email when new articles are posted on . Letermovir was first approved in 2017 for high-risk stem cell transplant recipients. CMV is relatively common in ...
Feasibility study of multiple HLA-class IA restricted peptide vaccines (KRM-19) for metastatic triple negative breast cancer (TNBC). Trials in progress: A phase II study of in situ therapeutic ...
Outcome disparities in elder patients with colorectal cancer receiving definitive surgery: A nationwide population-based study in Taiwan. This is an ASCO Meeting Abstract from the 2017 ASCO Annual ...
Credit: Getty Images This review provides a concise overview of the epidemiology, etiology, history, diagnostic criteria, and management of CMV infection in solid organ transplant recipients.
The US Food and Drug Administration (FDA) has approved letermovir (Prevymis) for the additional indication of prevention of cytomegalovirus in high-risk adult kidney transplant recipients. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results